Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides

Biogen Inc BIIB posted Q3 FY23 sales of $2.53 billion, beating the consensus of $2.39 billion, up 1% Y/Y and 3% at constant currency (CC).

Adjusted EPS of $4.36, down 9%, beating the consensus of $3.97.

Multiple sclerosis revenue of $1.16 billion decreased by 14% (down 12% CC). Multiple sclerosis drug Tysabri sales are down to $456.3 million from $505.5 million.

Spinraza's revenue of $448.2 million compared to $431.1 million a year ago.

Third quarter 2023 in-market product revenue for Leqembi recorded by Eisai Co Ltd ESALY was approximately $2 million.

Also Read: FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another.

Guidance: For the full year 2023, Biogen is updating its guidance ranges to reflect the completed acquisition of Reata and its previously projected dilution to 2023 Non-GAAP diluted EPS, regulatory approval for Zurzuvae in PPD, and the modification made to the presentation of Leqembi expenses. 

Biogen revises its FY23 revenues to decline in a low-single-digit percentage versus FY22 compared to earlier guidance of a mid-single-digit percentage decline.

The company expects an adjusted $14.50-$15.00, reflecting ~$0.75 of dilution from the Reata acquisition compared to prior guidance of $15.00-$16.00 and consensus of $15.23.

Price Action: BIIB shares are trading lower by 4.60% at $234.32 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!